Abstract
Glipizide (Fig. 1), indicated for the treatment of nonketotic maturity onset diabetes, is among the newest of the second generation sulfonylureas and is characterized by increased potency resulting in clinical effectiveness at relatively low milligram doses.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Similar content being viewed by others
References
Corrali, R.J.M., et al. (1976). Acta Therapeutica 2, 77.
Cochet, B., et al. (1975) Schweiz. Rundschau. Med. (PRAXIS) 64, 562.
Data on file 1978 Pfizer Laboratories, Pfizer, Inc.
Fahre, J., et al. (1973). Xllth International Congress of Therapeutics, Geneva, Sept. 24.
Pedrazzi, F., et al. (1971). Arzneim. Forsch. (Drug Res.) 21, No. 2, 220.
Lebovitz, H.E., et al. (1977) J. Clin. Endocrinol. Metab. 45, 601.
Sachs, R., et al. (1979) Marco Island Symposium on Glipizide, 1977. Excerpta Medica (In Press).
Parodi, F.A., and Caputo, G. (1974). Curr. Med. Res. Opin. 3 Suppl. 1, 31.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1979 Plenum Press, New York
About this chapter
Cite this chapter
Norris, E. (1979). Glipizide: A New Second Generation Sulfonylurea. In: Camerini-Davalos, R.A., Hanover, B. (eds) Treatment of EARLY DIABETES. Advances in Experimental Medicine and Biology, vol 119. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-9110-8_62
Download citation
DOI: https://doi.org/10.1007/978-1-4615-9110-8_62
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4615-9112-2
Online ISBN: 978-1-4615-9110-8
eBook Packages: Springer Book Archive